HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,015.00
-140.00 (-4.44%)
At close: Mar 20, 2026
Market Cap265.79B -67.4%
Revenue (ttm)63.25B +16.8%
Net Income-7.99B
EPS-90.75
Shares Out88.16M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume602,365
Average Volume512,882
Open3,125.00
Previous Close3,155.00
Day's Range3,015.00 - 3,240.00
52-Week Range2,404.76 - 9,857.14
Beta-0.94
RSI55.90
Earnings DateFeb 20, 2026

About HLB Therapeutics

HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers. The company was formerly known as G-treeBNT Co., Ltd. and changed its name to HLB... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 49
Stock Exchange KOSDAQ
Ticker Symbol 115450
Full Company Profile

Financial Performance

In 2024, HLB Therapeutics's revenue was 54.93 billion, an increase of 4.45% compared to the previous year's 52.59 billion. Losses were -22.79 billion, 890.1% more than in 2023.

Financial Statements